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The detection of malignant cells in fine-needle aspirates (FNA’s) using marker genes is hampered by the fact that these markers are
only expressed by certain malignancies or lack sensitivity and/or specificity. Here we report the results of a prospective pilot study
examining the expression of KOC (KH-domain containing protein over expressed in cancer), a novel onco-foetal gene, in 76 patients
who underwent fine-needle aspiration for further diagnosis of abdominal lesions, aszites, cysts or cerebrospinal fluid. Aspirates were
examined by cytology and by a KOC RT–PCR assay. KOC expression was a highly sensitive and specific indicator of malignancy. The
KOC assay could be useful to facilitate screening for malignant disease and to improve the diagnostic accuracy of FNAs.
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In a large-scale screen for differentially expressed genes in
pancreatic cancer, we have recently identified a gene encoding a
novel protein with four K-homologous (KH) domains, which is
highly overexpressed in pancreatic cancer (Mueller-Pillasch et al,
1997). The new gene was named KOC (KH-domain containing
protein overexpressed in cancer). Two known functions of KH-
domain containing proteins are the regulation of mRNA stability
and subcellular localisation, both of which are implicated in
fundamental biological processes such as development, cell
growth, differentiation and carcinogenesis (Ross et al, 1997).
Therefore, KOC may play a role in the regulation of tumour cell
proliferation by interfering with transcriptional and/or post-
transcriptional processes. However, the precise role of KOC in
tumour biology remains to be elucidated. Our preliminary data
suggested that KOC is exclusively expressed in tumours and
embryonic tissues (Mueller-Pillasch et al, 1997, 1999) and may
therefore represent an ideal target for novel diagnostic approaches.
To test this hypothesis, a prospective study was undertaken to
determine the diagnostic accuracy of measuring KOC expression
as compared to the cytological assessment in a consecutive series
of fine-needle aspirates (FNAs) from abdominal lesions, aszites,
various cysts and cerebrospinal fluid.
MATERIALS AND METHODS
Determination of KOC expression in cell lines and FNAs
Human Panc-1 pancreatic cancer cells were purchased from the
American Type Culture Collection. Stocks were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% (vv
 1) foetal bovine serum (FBS) in a humidified atmosphere
of 5% CO2/95% air at 371C and passaged every 3 days. Confluent
cultures of Panc-1 cells were trypsinised and resuspended in
serum-free DMEM. Various numbers of Panc-1 cells were
subsequently mixed with 1ml of human serum and then
immediately centrifuged at 1200r.p.m. for 2min. The supernatants
were decanted. The remaining cell pellets were resuspended in the
RNeasy Mini Kit lysis buffer (Qiagen, Hilden, Germany) and total
RNA was extracted using the same kit according to the
manufacturer’s instructions. cDNA synthesis and PCR were
performed with the one-step RT–PCR (Polymerase Chain Reac-
tion) Kit (Qiagen, Hilden, Germany) using KOC gene-specific
primers. Annealing temperature was 551C for 32 cycles. PCR
products were run on a 1% agarose/TAE gel and stained with
ethidium bromide. Diagnostic FNAs of various abdominal lesions
or fluids were obtained by ultrasonography-guided biopsy using a
0.7mm Chiba needle. The first blowout of the needle was used for
cytology. Cells remaining in the needle were flushed into a vial
with sodium chloride and subsequently further analysed for KOC
expression as described above. Informed consent of all patients
was obtained prior to the procedure. The KOC RT–PCR assays
and the cytological examination were performed independently in
a blinded fashion by different researchers. The diagnostic
sensitivity of cytology and the KOC RT–PCR assay was
determined as the frequency of samples correctly identified as
malignant/positive by each examination among the number of
correctly identified positive cases plus the number of false-negative
cases. The diagnostic specificity of cytology and the KOC RT–PCR
assay was determined as the frequency of samples correctly
identified as benign/negative by each examination among the
number of correctly identified negative cases plus the number of
false-positive cases.
RESULTS AND DISCUSSION
To determine the number of cells required to detect KOC
transcripts, various numbers of Panc-1 human pancreatic cancer
cells, which express KOC (Mueller-Pillasch et al, 1997), were mixed
with 1ml of human serum. As few as 50 cancer cells were sufficient
to demonstrate KOC transcripts in this cell line (Figure 1A). Revised 15 October 2002; accepted 28 November 2002
*Correspondence: Dr T Seufferlein, Department of Internal Medicine I,
Medical University of Ulm, Robert-Koch-Str. 8, D-89081 Ulm, Germany;
E-mail: thomas.seufferlein@medizin.uni-ulm.de
3Both authors contributed equally.
British Journal of Cancer (2003) 88, 699–701
& 2003 Cancer Research UK All rights reserved 0007– 0920/03 $25.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yThe first blowout containing the majority of the aspirate was
always used for the cytological assessment to assure optimal
conditions for cytology. The second blowout was used to determine
KOC expression. Using this approach KOC transcripts were clearly
detectable in aspirates of various malignant lesions (Figure 1B).
Having established that KOC transcripts could be detected
under these conditions, aspirates of 48 patients (20 women and 28
men, median age of 62.5 and 59.7 years, respectively; range 45–77
and 27–82 years, respectively) who underwent FNA for further
diagnosis of an abdominal lesion (median size 4.4cm; range 1.1–
10cm) were examined by cytology and the KOC RT–PCR assay. A
definitive diagnosis could be obtained in 41 patients by cytology or
by additional histological examination of specimens obtained by
trucut biopsy or surgical procedures. In another seven patients, the
initial cytological assessment was indeterminate, but these patients
were not available for a further FNA. Thus, those 41 cases with a
definitive cytological assessment and/or histological confirmation
were enrolled in the study.
By initial cytological analysis, 24 out of 41 FNAs were diagnosed
as malignant (Table 1A). A total of 23 of these samples were also
KOC positive. Only in one sample KOC transcripts could not be
detected. Four lesions were classified as indeterminate by cytology.
In two of these lesions malignant disease was subsequently
detected on repeat biopsy. In these two lesions, KOC transcripts
were already detected in the first FNA. Another two of the initially
indeterminate lesions were subsequently classified as benign on
repeat biopsy. One of these lesions was KOC negative in the first
FNA. However, KOC transcripts were detected in the other lesion.
In total, 13 samples were initially classified as benign by cytology.
However, in four of these patients, malignant disease was strongly
suspected and ultimately confirmed on repeat biopsy. All four
samples were KOC positive already in the first assessment.
Another nine lesions were negative by both cytology as well as
the KOC assay. The sites of abdominal lesions and the confirmed
diagnoses are shown in Table 1B.
Diagnostic sensitivity and specificity of the KOC assay in FNAs
were 93% (29 out of 31) and 83% (10 out of 12), respectively.
0 100 10 50 1 2 No. of cells 3 4 A B
Figure 1 Expression of KOC in pancreatic cancer cells and tissue
samples of various cancers. (A) Various numbers of Panc-1 cells were
mixed with 1ml of human serum and then immediately centrifuged at
1200r.p.m. for 2min. Total RNA was extracted and KOC expression was
determined by RT–PCR as described in Materials and Methods. (B)
Typical results of KOC RT–PCR assays performed as described above
using RNA extracted from residual cells in the aspiration needle after FNA:
1¼normal pancreas, 2¼metastasis of colorectal cancer, 3¼lymphoma,
4¼hepatocellular carcinoma. Samples 2–4 are classified as KOC positive.
Table 1 (A) Summary of the results of the initial cytological and subsequent histological analysis of repeat biopsies and the KOC RT–PCR assay in FNA
samples
a and >(B) Clinical characteristics of patients undergoing FNA
(A)
No. of patients Cytology Repeat biopsies KOC Confirmed diagnosis
Malignant/benign
23 + + 23/0
1+   1/0
2 ? + + 2/0
1?   + 0/1
1?    0/1
4   + + 4/0
9    0/9
T=41
(B)
No. of patients Localisation of lesion Cyto/Histo + KOC + Cyto/Histo   KOC   Confirmed diagnosis
3 Liver 3 3 Colorectal cancer
1 Spleen 1 1 Colorectal cancer
1 Retrocaval lymph node 1 1 Colorectal cancer
1 Liver 1 1 Pancreatic cancer
5 Pancreas 6 6 Pancreatic cancer
7 Liver 7 6 1 Cancer of unknown primary
4 Truncal lymph node 3 4 1 Lymphoma
2 Liver 2 2 Hepatocellular carcinoma
1 Peripancreatic lymph node 1 1 Plasmocytoma
1 Spleen 1 1 Lung cancer
1 Liver 1 1 Breast cancer
1 Liver 1 1 Gastric cancer
1 Pelvis 1 1 Ovarian cancer
1 Pancreas 1 1 Renal cancer
4 Liver 4 4 Not malignant disease
3 Pancreas 2 2 Not malignant disease
3 Mediastine 3 3 Not malignant disease
1 Pelvis 1 1 Not malignant disease
T=41 30 30 11 11
a+=expression of KOC or lesion classified as malignant in cytology and/or histology;  =no expression of KOC detectable or lesion classified as benign in cytology and/or
histology. ?=lesion classified as indeterminate in cytology. T¼total.
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difficult. Therefore, we examined whether the KOC assay could
also be useful to detect malignant cells in aspirates of fluids.
Aspirates included aszites, fluid from liver, pancreatic and
mediastinal cysts as well as cerebrospinal fluid. In total, 50
aspirates were examined. In 35 aspirates from 35 patients, a
definitive cytological statement could be obtained (13 women and
22 men, median age of 59.1 and 60.5 years, respectively; range
22–86 and 22–92 years, respectively; for patient characteristics,
see Table 2). Subsequently, these 35 aspirates were also examined
for KOC expression.
In total, nine aspirates were cytologically diagnosed as
malignant and 26 as benign. KOC expression was detected in all
nine cytologically malignant aspirates. All 26 cytologically benign
samples were also KOC negative. In particular, we obtained 15
samples of cerebrospinal fluid from patients who presented with
acute leukaemia or lymphoma and underwent lumbar puncture to
determine involvement of the central nervous system. Three of
these samples were classified as malignant by cytology. KOC
expression was detected in all three samples. In contrast, the 13
samples classified as benign by cytology exhibited no KOC
transcripts (Table 2).
Thus, diagnostic sensitivity and specificity of the KOC assay in
these aspirates was 100% if cytology is taken as the gold standard.
The aspirates of seven patients were classified as benign by
cytology and KOC negative despite the fact that these patients were
diagnosed with a malignant disease. However, more invasive
procedures to further investigate the existence of malignant cells in
these fluids were not justified from a medical point of view.
The data of our pilot study establish a striking difference in KOC
expression between malignant and benign lesions. KOC transcripts
are expressed by a broad spectrum of malignant cells originating
from primary epithelial tumours, metastases and even haemato-
poietic malignancies. KOC transcripts can be detected in samples
that are readily obtainable such as FNAs and aspirates including
cerebrospinal fluid with a high sensitivity and specificity.
Various screening markers have been tried to increase the
diagnostic accuracy in FNAs and aspirates. However, these
markers remain unsatisfactory because of their low sensitivity
and/or specificity or because of their limited applicability, for
example, telomerase in breast lesions (Clark et al, 1997) or ret/PTC
rearrangements in thyroid cancer (Cheung et al, 2001). The KOC
assay is generally applicable and could be a useful novel tool to
refine the FNA diagnosis of malignancy by reducing the number of
additional procedures required to establish a suspected diagnosis
of malignancy. The assay facilitates the screening for malignant
disease, but could also be used to monitor therapeutic efficacy, for
example, in cerebrospinal fluid. Further studies are needed to
determine the onset of KOC expression during carcinogenesis and
to establish whether detection of KOC transcripts could be even
useful as an early indicator of malignancy.
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